Physician profile
Daniel Wayne Wilson
NPI 1700977592
$12,040.73
in general payments reported to CMS, 2019-2025
45 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $1,609 · 2021: $2,150 · 2022: $1,868 · 2023: $1,799 · 2024: $1,682 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,131 · Education: $20.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,130.59 |
| Education | $20.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,759.90 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,689.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,428.61 | 2019-2025 | Farxiga, Brilinta, Breztri |
| Lilly USA, LLC | $1,109.82 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $813.11 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.29 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $345.70 | 2019-2024 | |
| Astellas Pharma US INC | $315.31 | 2019-2025 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $301.19 | 2019-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $297.42 | 2022-2025 | |
| Amgen INC. | $273.40 | 2019-2025 | Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $255.93 | 2019-2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $247.15 | 2019-2022 | |
| Allergan, INC. | $235.11 | 2019-2020 | |
| Corcept Therapeutics | $226.18 | 2024-2025 | Korlym |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $200.82 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $181.63 | 2019-2022 | |
| Glaxosmithkline, LLC. | $177.95 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $168.06 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.00 | 2020-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $151.80 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $145.87 | 2020-2022 | |
| Eisai INC. | $130.91 | 2020-2022 | |
| Abbott Laboratories | $107.29 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Esperion Therapeutics, INC. | $104.31 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.92 | 2023-2025 | Caplyta |
| Sanofi Pasteur INC. | $64.46 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $61.96 | 2024-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $61.21 | 2022-2024 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $56.26 | 2023-2024 | |
| Boston Scientific Corporation | $46.69 | 2022-2025 | Watchman Access System |
| Axsome Therapeutics, INC. | $36.91 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $36.09 | 2024 | Rexulti |
| Biodelivery Sciences International, INC. | $34.49 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $29.15 | 2021-2023 | Crysvita |
| Scilex Pharmaceuticals INC. | $28.46 | 2021 | |
| Arbor Pharmaceuticals, INC. | $27.32 | 2021 | |
| Nevro Corp. | $23.85 | 2022 | |
| Inspire Medical Systems, INC. | $22.22 | 2025 | Inspire |
| Azurity Pharmaceuticals, INC. | $16.38 | 2023 | Edarbi |
| Almatica Pharma LLC | $16.27 | 2025 | Loreev Xr |
| Amneal Pharmaceuticals LLC | $14.82 | 2025 | Unithroid |
| Horizon Therapeutics Plc | $14.22 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.06 | 2024 | Quviviq |
| Lundbeck LLC | $13.92 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.